Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.37 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.33 |
| ▸ | CA12 | O43570 | 2/20 | 0.32 |
| ▸ | CA1 | P00915 | 2/20 | 0.32 |
| ▸ | CA2 | P00918 | 1/20 | 0.32 |
| ▸ | CA9 | Q16790 | 1/20 | 0.32 |
| ▸ | CA7 | P43166 | 1/20 | 0.31 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.31 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | CTSL | P07711 | 1/20 | 0.31 |
| ▸ | CTSK | P43235 | 1/20 | 0.30 |
| ▸ | NR1D1 | P20393 | 1/20 | 0.30 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5551672 | 0.83 | CYP2D6 (0.35) | CYP2C19CYP2D6CA12CA1CA2 | |
| SCHEMBL19661282 | 0.81 | CA1 (0.44) | CYP1A2CYP2C9CYP2C19HTTSMN1; SMN2 | |
| SCHEMBL8777319 | 0.79 | TDP1 (0.41) | CYP2C19CYP2D6CA1CA2 | |
| SCHEMBL8719360 | 0.78 | CASR (0.30) | CYP2D6NR1D1 | |
| SCHEMBL19458 | 0.77 | TDP1 (0.42) | CYP2C19SMN1; SMN2CYP2D6CA12CA1 | |
| SCHEMBL18362421 | 0.76 | CA12 (0.48) | CYP1A2CYP2C9CYP2C19HTTSMN1; SMN2 | |
| SCHEMBL7567960 | 0.74 | CHRM2 (0.37) | CYP2C19SMN1; SMN2CA12CA1CA7 | |
| SCHEMBL25453034 | 0.73 | CYP2D6 (0.33) | CYP2D6CA12CA1CA7CA14 | |
| SCHEMBL23711054 | 0.73 | CA12 (0.36) | CYP2C19CYP2D6CA12CA1CA7 | |
| SCHEMBL7662090 | 0.73 | CTSS (0.33) | CYP2D6CTSK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7211241-B2 | Cascade polymer complexes, process for their production and pharmaceutical agents containing said complexes | SCHERING AKTIENGESELLSCHAFT (DE) | 2007-05-01 | — | — | US | disclosed |
| US-6861043-B2 | Cascade polymer complexes, process for their production and pharmaceutical agents containing said complexes | SCHERING AG (DE) | 2005-03-01 | — | — | US | disclosed |
| US-20040091426-A1 | Cascade polymer complexes, process for their production and pharmaceutical agents containing said complexes | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2004-05-13 | — | — | US | disclosed |
| US-20020187101-A1 | Cascade polymer complexes, process for their production and pharmaceutical agents containing said complexes | SCHERING AG (DE) | 2002-12-12 | — | — | US | disclosed |
| EP-0836485-B1 | CASCADE POLYMER COMPLEXES | SCHERING AG (DE) | 2002-07-24 | — | — | EP | disclosed |
| US-6177060-B1 | NMR OR X-RAY LYMPHOGRAPHY IMAGES | SCHERING AKTIENGESEUSCHAFT (DE) | 2001-01-23 | — | — | US | disclosed |
| US-6063361-A | ADMINISTERING TO A PATIENT AT LEAST ONE CASCADE POLYMER COMPLEX AND SUBJECTING THE PATIENT TO A RADIOLOGY DIAGNOSIS | SCHERING AKTIENGESELLSCHAFT (DE) | 2000-05-16 | — | — | US | disclosed |
| US-5820849-A | DIAGNOSIS WITH NUCLEAR MAGNETIC RESONANCE | SCHERING AKTIENGESELLSCHAFT (DE) | 1998-10-13 | — | — | US | disclosed |
| EP-0836485-A2 | CASCADE POLYMER COMPLEXES | SCHERING AKTIENGESELLSCHAFT (DE) | 1998-04-22 | — | — | EP | disclosed |
| WO-1997002051-A2 | CASCADE POLYMER COMPLEXES | SCHERING AKTIENGESELLSCHAFT (DE) | 1997-01-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040091426-A1 | Cascade polymer complexes, process for their production and pharmaceutical agents containing said complexes | ZYX, CCNY, MOK | CYP1A2 3235/4885CYP2C9 3418/4885CYP2C19 3095/4885 |
| US-20020187101-A1 | Cascade polymer complexes, process for their production and pharmaceutical agents containing said complexes | TFPI, LYN, SYK | CYP1A2 3599/4885CYP2C9 1881/4885CYP2C19 2300/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.